307 related articles for article (PubMed ID: 16266436)
41. Cerebrospinal fluid pleocytosis is associated with HIV-1 neuroinvasion during acute infection.
Chan P; Moreland S; Sacdalan C; Kroon E; Colby D; Sriplienchan S; Pinyakorn S; Phanuphak N; Jagodzinski L; Valcour V; Vasan S; Paul R; Trautmann L; Spudich S;
AIDS; 2024 Mar; 38(3):373-378. PubMed ID: 37916464
[TBL] [Abstract][Full Text] [Related]
42. Factors associated with cerebrospinal fluid HIV RNA in HIV infected subjects undergoing lumbar puncture examination in a clinical setting.
Rawson T; Muir D; Mackie NE; Garvey LJ; Everitt A; Winston A
J Infect; 2012 Sep; 65(3):239-45. PubMed ID: 22522289
[TBL] [Abstract][Full Text] [Related]
43. Cerebrospinal Fluid Viral Load Across the Spectrum of Untreated Human Immunodeficiency Virus Type 1 (HIV-1) Infection: A Cross-Sectional Multicenter Study.
Ulfhammer G; Edén A; Antinori A; Brew BJ; Calcagno A; Cinque P; De Zan V; Hagberg L; Lin A; Nilsson S; Oprea C; Pinnetti C; Spudich S; Trunfio M; Winston A; Price RW; Gisslén M
Clin Infect Dis; 2022 Aug; 75(3):493-502. PubMed ID: 34747481
[TBL] [Abstract][Full Text] [Related]
44. Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load.
Peluso MJ; Ferretti F; Peterson J; Lee E; Fuchs D; Boschini A; Gisslén M; Angoff N; Price RW; Cinque P; Spudich S
AIDS; 2012 Sep; 26(14):1765-74. PubMed ID: 22614889
[TBL] [Abstract][Full Text] [Related]
45. Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. HIV Neurobehavioral Research Center Group.
Ellis RJ; Hsia K; Spector SA; Nelson JA; Heaton RK; Wallace MR; Abramson I; Atkinson JH; Grant I; McCutchan JA
Ann Neurol; 1997 Nov; 42(5):679-88. PubMed ID: 9392566
[TBL] [Abstract][Full Text] [Related]
46. Low blood CD8+ T-lymphocytes and high circulating monocytes are predictors of HIV-1-associated progressive encephalopathy in children.
Sánchez-Ramón S; Bellón JM; Resino S; Cantó-Nogués C; Gurbindo D; Ramos JT; Muñoz-Fernández MA
Pediatrics; 2003 Feb; 111(2):E168-75. PubMed ID: 12563091
[TBL] [Abstract][Full Text] [Related]
47. Temporal Patterns and Drug Resistance in CSF Viral Escape Among ART-Experienced HIV-1 Infected Adults.
Mukerji SS; Misra V; Lorenz D; Cervantes-Arslanian AM; Lyons J; Chalkias S; Wurcel A; Burke D; Venna N; Morgello S; Koralnik IJ; Gabuzda D
J Acquir Immune Defic Syndr; 2017 Jun; 75(2):246-255. PubMed ID: 28328546
[TBL] [Abstract][Full Text] [Related]
48. Low levels of HIV-1 RNA detected in the cerebrospinal fluid after up to 10 years of suppressive therapy are associated with local immune activation.
Dahl V; Peterson J; Fuchs D; Gisslen M; Palmer S; Price RW
AIDS; 2014 Sep; 28(15):2251-8. PubMed ID: 25022595
[TBL] [Abstract][Full Text] [Related]
49. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V;
J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728
[TBL] [Abstract][Full Text] [Related]
50. Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy.
Canestri A; Lescure FX; Jaureguiberry S; Moulignier A; Amiel C; Marcelin AG; Peytavin G; Tubiana R; Pialoux G; Katlama C
Clin Infect Dis; 2010 Mar; 50(5):773-8. PubMed ID: 20100092
[TBL] [Abstract][Full Text] [Related]
51. Central nervous system immune activation characterizes primary human immunodeficiency virus 1 infection even in participants with minimal cerebrospinal fluid viral burden.
Spudich S; Gisslen M; Hagberg L; Lee E; Liegler T; Brew B; Fuchs D; Tambussi G; Cinque P; Hecht FM; Price RW
J Infect Dis; 2011 Sep; 204(5):753-60. PubMed ID: 21844301
[TBL] [Abstract][Full Text] [Related]
52. A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.
García F; Romeu J; Grau I; Sambeat MA; Dalmau D; Knobel H; Gomez-Sirvent JL; Arrizabalaga J; Cruceta A; Clotet BG; Podzamczer D; Pumarola T; Gallart T; O'Brien WA; Miró JM; Gatell JM
AIDS; 1999 Dec; 13(17):2377-88. PubMed ID: 10597779
[TBL] [Abstract][Full Text] [Related]
53. Predictive factors influencing peak viral load drop in response to nucleoside reverse transcriptase inhibitors in antiretroviral-naive HIV-1-infected patients.
Vidal C; García F; Gatell JM; Leal M; Clotet B; Pumarola T; Miró JM; Mallolas J; Ruiz L; Cruceta A; Tortajada C
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Sep; 19(1):55-60. PubMed ID: 9732070
[TBL] [Abstract][Full Text] [Related]
54. Persistent HIV-infected cells in cerebrospinal fluid are associated with poorer neurocognitive performance.
Spudich S; Robertson KR; Bosch RJ; Gandhi RT; Cyktor JC; Mar H; Macatangay BJ; Lalama CM; Rinaldo C; Collier AC; Godfrey C; Eron JJ; McMahon D; Jacobs JL; Koontz D; Hogg E; Vecchio A; Mellors JW
J Clin Invest; 2019 Jul; 129(8):3339-3346. PubMed ID: 31305262
[TBL] [Abstract][Full Text] [Related]
55. Cerebrospinal fluid HIV-1 RNA, intrathecal immunoactivation, and drug concentrations after treatment with a combination of saquinavir, nelfinavir, and two nucleoside analogues: the M61022 study.
Yilmaz A; Fuchs D; Hagberg L; Nillroth U; Ståhle L; Svensson JO; Gisslén M
BMC Infect Dis; 2006 Mar; 6():63. PubMed ID: 16566834
[TBL] [Abstract][Full Text] [Related]
56. HIV-1 RNA levels in cerebrospinal fluid and plasma and their correlation with opportunistic neurological diseases in a Brazilian AIDS reference hospital.
Christo PP; Greco DB; Aleixo AW; Livramento JA
Arq Neuropsiquiatr; 2005 Dec; 63(4):907-13. PubMed ID: 16400403
[TBL] [Abstract][Full Text] [Related]
57. Estimation of virological and immunological parameters in subjects from South India infected with human immunodeficiency virus type 1 clade C and correlation of findings with occurrence of neurological disease.
Kamat A; Ravi V; Desai A; Satishchandra P; Satish KS; Kumar M
J Neurovirol; 2009 Jan; 15(1):25-35. PubMed ID: 19031329
[TBL] [Abstract][Full Text] [Related]
58. Quantifying HIV-1 RNA using the polymerase chain reaction on cerebrospinal fluid and serum of seropositive individuals with and without neurologic abnormalities.
Conrad AJ; Schmid P; Syndulko K; Singer EJ; Nagra RM; Russell JJ; Tourtellotte WW
J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Dec; 10(4):425-35. PubMed ID: 7583438
[TBL] [Abstract][Full Text] [Related]
59. Symptomatic cerebrospinal fluid escape.
Mastrangelo A; Turrini F; de Zan V; Caccia R; Gerevini S; Cinque P
AIDS; 2019 Dec; 33 Suppl 2():S159-S169. PubMed ID: 31789816
[TBL] [Abstract][Full Text] [Related]
60. HIV-1 viral load and CD4 cell count in untreated children with vertically acquired asymptomatic or mild disease. Paediatric European Network for Treatment of AIDS (PENTA).
AIDS; 1998 Mar; 12(4):F1-8. PubMed ID: 9520161
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
